Related references
Note: Only part of the references are listed.Subchronic phencyclidine in rats: alterations in locomotor activity, maze performance, and GABAA receptor binding
Richard J. Beninger et al.
BEHAVIOURAL PHARMACOLOGY (2010)
Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease
Robert Schwarcz et al.
PROGRESS IN NEUROBIOLOGY (2010)
L-kynurenine treatment alters contextual fear conditioning and context discrimination but not cue-specific fear conditioning
Amy C. Chess et al.
BEHAVIOURAL BRAIN RESEARCH (2009)
Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: implications for schizophrenia
Sara K. Olsson et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2009)
On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo
Laura Amori et al.
JOURNAL OF NEUROCHEMISTRY (2009)
Clozapine interacts with the glycine site of the NMDA receptor: Electrophysiological studies of dopamine neurons in the rat ventral tegmental area
Lilly Schwieler et al.
LIFE SCIENCES (2008)
Induction of indolamine 2,3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge:: A role for IFN-γ?
Thomas J. Connor et al.
NEUROSCIENCE LETTERS (2008)
Activation of rat ventral tegmental area dopamine neurons by endogenous kynurenic acid: A pharmacological analysis
Klas R. Linderholm et al.
NEUROPHARMACOLOGY (2007)
Elevations of endogenous kynurenic acid produce spatial working memory deficits
Amy C. Chess et al.
SCHIZOPHRENIA BULLETIN (2007)
Increased concentration of cerebral kynurenic acid alters stimulus processing and conditioned responding
Amy C. Chess et al.
BEHAVIOURAL BRAIN RESEARCH (2006)
Subchronic treatment with kynurenine and probenecid: effects on prepulse inhibition and firing of midbrain dopamine neurons
LK Nilsson et al.
JOURNAL OF NEURAL TRANSMISSION (2006)
Effects of COX-1 and COX-2 inhibitors on the firing of rat midbrain dopaminergic neurons - Possible involvement of endogenous kynurenic acid
L Schwieler et al.
SYNAPSE (2006)
Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease
MT Sapko et al.
EXPERIMENTAL NEUROLOGY (2006)
Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia
LK Nilsson et al.
SCHIZOPHRENIA RESEARCH (2005)
Structural studies on 3-hydroxyanthranilate-3,4-dioxygenase: The catalytic mechanism of a complex oxidation involved in NAD biosynthesis
Y Zhang et al.
BIOCHEMISTRY (2005)
Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum
A Rassoulpour et al.
JOURNAL OF NEUROCHEMISTRY (2005)
Endogenous kynurenic acid disrupts prepulse inhibition
S Erhardt et al.
BIOLOGICAL PSYCHIATRY (2004)
Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat
PD Shepard et al.
NEUROPSYCHOPHARMACOLOGY (2003)
Effects of systemic and central nervous system localized inflammation on the contributions of metabolic precursors to the L-kynurenine and quinolinic acid pools in brain
T Kita et al.
JOURNAL OF NEUROCHEMISTRY (2002)
Increased phasic activity of dopaminergic neurones in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynurenic acid
S Erhardt et al.
ACTA PHYSIOLOGICA SCANDINAVICA (2002)
Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia
S Erhardt et al.
NEUROSCIENCE LETTERS (2001)
Increased cortical kynurenate content in schizophrenia
R Schwarcz et al.
BIOLOGICAL PSYCHIATRY (2001)
Presynaptic kynurenate-sensitive receptors inhibit glutamate release
R Carpenedo et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2001)
Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons
S Erhardt et al.
AMINO ACIDS (2001)
Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: Implications for schizophrenia
LS Kegeles et al.
BIOLOGICAL PSYCHIATRY (2000)